SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Patrick Forde

Patrick Forde

Trinity St James's Cancer Institute, Dublin

Prof. Patrick Forde is the Patrick Prendergast Professor of Clinical Immuno-Oncology at the Trinity St James’s Cancer Institute, Trinity College Dublin, and a Consultant Medical Oncologist at St James’s Hospital, Dublin. He led the development of neoadjuvant immunotherapy for resectable lung cancer from first-in-human proof of concept to global practice, serving as principal investigator of the CheckMate 816 trial that established neoadjuvant chemo-immunotherapy for stage II-III non-small cell lung cancer, and his work also extends to malignant pleural mesothelioma. He previously built this research program at Johns Hopkins University in Baltimore before moving to Dublin in 2024, and is a frequent speaker at major international thoracic oncology congresses.

Connect

Patrick Forde

Featured in

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates